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Is homocysteine an iron-
dependent cardiovascular risk 
factor?
JL Sullivan1
Recent studies of endothelial function suggest that adverse vascular 
effects of homocysteine are iron-dependent. Iron sucrose worsens 
and iron chelation eliminates homocysteine-associated decreases 
in flow-mediated dialation. There may be no vasculopathic effect 
of homocysteine without available reactive iron. Iron-dependent 
amplification of the vascular effects of homocysteine may be one of 
several mechanisms by which stored iron increases cardiac risk.
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Th e ‘iron hypothesis’ suggests that a state 
of sustained iron depletion exerts primary 
protective eff ects against ischemic heart 
disease. Th e idea was originally formu-
lated in 1981 as an explanation for the 
low cardiac disease rates of menstruat-
ing women.1 Iron storage levels are kept 
low by regular menstrual iron losses until 
the cessation of menses, aft er which heart 
disease risk escalates in parallel with the 
acquisition of stored iron. Th e inadequacy 
of the traditional hormonal explanation 
for the risk increase was an important 
motivation for seeking an alternative 
explanation. The shortcomings of the 
hormonal explanation were apparent 
from fi ndings available in 1981. Now that 
prospective results of the Women’s Health 
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Initiative HRT trial have shown that exog-
enous female hormones not only fail to 
protect, but slightly boost, rates of heart 
disease, it is more urgent that attention be 
focused on alternative explanations.2
One such alternative hypothesis 
involves homocysteine. In 1983, it was 
observed that premenopausal women 
have a “unique effi  ciency of methionine 
metabolism” that results in lower homo-
cysteine levels aft er methionine loading 
than are seen in men or postmenopausal 
women.3 Th e authors hypothesized that 
premenopausal women, for unknown rea-
sons, might remethylate homocysteine to 
methionine more effi  ciently, thus main-
taining a lower homocysteine concentra-
tion. Th is was proposed to be the basis for 
the sex diff erence in heart disease rates. 
A more recent study found that young 
women do have a significantly higher 
rate of homocysteine remethylation than 
young men, although no sex diff erence 
in resting or post-methionine loading 
plasma homocysteine concentrations 
could be documented.4 Other investiga-
tors have reported lower homocysteine 
levels in menstruating women.5
A pattern of lower homocysteine 
concentration in menstruating women 
that rises to the male level aft er meno-
pause would be expected if iron deple-
tion increased the rate of homocysteine 
remethylation. Such an eff ect remained 
speculative until the recent unexpected 
discovery that the iron storage protein, 
ferritin, has an important enzymatic 
function in folate catabolism.6 In general, 
higher intracellular ferritin levels are asso-
ciated with lower folate availability. As 
“purine biosynthesis, thymidylate biosyn-
thesis, and homocysteine remethylation 
vie for a limited pool of folate-activated 
one-carbon units,” it appears that ferritin-
mediated folate catabolism can result in 
higher homocysteine concentrations by 
minimizing the availability of one-carbon 
units for remethylation.7 I propose that, 
as more ferritin is synthesized to accom-
modate additional storage iron acquired 
aft er the cessation of menstrual blood loss, 
homocysteine remethylation rates dimin-
ish in proportion to the ferritin-mediated 
decline in available intracellular folate. 
Increased ferritin near sites of infl amma-
tion may increase local concentrations of 
Kidney International (2006) 69       643
commentar y
homocysteine by this mechanism even in 
individuals showing no systemic homo-
cysteine increase.
Th ere are signifi cant problems for the 
hypothesis that eff ects of gender and the 
menopausal transition on homocysteine 
concentration are the primary basis for 
the sex diff erence in heart disease rates. If 
these eff ects are a refl ection of diff erences 
in iron status, then the homocysteine 
changes are not primary, but are depend-
ent on the uncontroversial fact that iron 
loss stops with the cessation of menstrual 
blood loss.
Before the “increased efficiency of 
methionine metabolism” hypothesis can 
be accepted as an explanation of the sex 
diff erence, concerns about the magnitude 
of the homocysteine eff ects, as well as con-
tinuing uncertainty about the consistency 
of these changes aft er menopause, must 
be addressed. Th e question of magnitude 
is crucial, given the quite large protective 
eff ect of premenopausal status in contrast 
to the possibly limited benefi t expected 
from modestly lower homocysteine lev-
els.8,9 However, an amplifi ed risk increase 
in association with a small rise in homo-
cysteine could occur after menopause 
if some new factor appearing after the 
menopausal transition has the eff ect of 
synergistically boosting the vasculotoxic 
impact of homocysteine. Recent fi ndings 
suggest that the elevated iron levels of the 
postmenopausal condition could be such 
a risk-amplifying factor.
Th e study of Zheng et al.10 in this issue 
demonstrates that intravenous iron aug-
ments the deleterious eff ects of homo-
cysteine on endothelial function. It is a 
companion study to previous work by the 
same group in 200211 showing complete 
correction of the homocysteine-induced 
decrease in endothelial function by an 
iron chelator. Th e two studies show that 
transient perturbations of iron status have 
dramatic eff ects on the homocysteine-
induced inhibition of fl ow-mediated dila-
tation (FMD): increased iron worsens, and 
iron removal corrects, the defi cits. Th ese 
authors have also shown that changes in 
iron status associated with frequent blood 
donation are associated with a signifi cant 
increase in FMD.12,13 Taken together, the 
studies are of fundamental relevance to 
the status of homocysteine as an inde-
pendent cardiac risk factor, supporting the 
contention that adverse vascular eff ects of 
homocysteine are iron-dependent.
Future work should address the ques-
tion of how much protection against 
homocysteine can be achieved by limiting 
iron availability in vivo and—of particu-
lar importance from an epidemiological 
perspective—whether protection can 
also be achieved by reduction or com-
plete elimination of storage iron before 
a homocysteine challenge. Zheng et al.11 
suggested that dexrazoxane “did com-
pletely abrogate the methionine-induced 
reduction in FMD”; however, the data 
appear compatible with the conclusion 
that the iron chelator did not simply 
correct the homocysteine inhibition but 
caused an improvement in FMD over 
control levels (Figure 1). Th e data raise 
the possibility that larger concentrations 
of homocysteine may also be harmless 
to the endothelium if iron availability is 
suffi  ciently restricted either by short term 
chelation or by prior induction of a state 
of iron depletion.
Studies of the eff ect of lowered iron level 
on homocysteine concentrations should 
be useful in resolving discrepant fi ndings 
concerning associations of homocysteine 
with serum ferritin. Facchini and Saylor14 
reported that induced iron depletion to 
“near iron defi ciency” can lower levels 
of certain cardiac risk factors but has no 
eff ect on homocysteine level. Th e subjects 
in this study were carbohydrate-intolerant 
patients in whom homocysteine concen-
tration could be resistant to iron deple-
tion because of potentially confounding 
comorbidities. Such comorbidities are 
absent in younger, healthy premenopausal 
women. Relevant comorbidities possibly 
include renal disease. How much of the 
impaired homocysteine remethylation 
seen in renal disease15 is due to increased 
iron level is not known and should be 
investigated in future studies. Th e plasma 
levels of homocysteine and ferritin may 
not be adequate indicators of their local 
concentrations at sites of infl ammation.
A key feature of the proposals presented 
here concerns the relationship between 
stored iron and the availability of reac-
tive iron in vivo. It has been suggested 
that reactive iron available for harmful 
interactions such as that reported with 
homocysteine is proportional to storage 
iron level, and that reactive iron availa-
bility approaches its minimum in vivo in 
the state of iron depletion.16 Th e strongest 
evidence in support of this possibility is 
provided by studies of induced iron deple-
tion. Such studies (reviewed in ref. 16) 
support the idea that complete removal 
of stored iron produces signifi cant anti-
oxidant and anti-infl ammatory eff ects in 
vivo. Th is concept is also consistent with 
the recent discovery that low storage iron 
levels in frequent volunteer blood donors 
are associated with increased FMD.12
Studies concluding that homocysteine 
is an independent cardiac risk factor have 
almost universally ignored potential inter-
actions with iron such as those demon-
strated by Zheng et al.10,11 Relevant work 
has generally been accomplished without 
modifi cations of iron concentration and 
usually without specifi c knowledge of the 
iron status in the system under study. It 
is likely that most epidemiological and 
experimental studies have been con-
ducted under conditions in which iron 
is available in abundance. Th e work of 
Zheng et al.10,11 raises the possibility that 
there may be no inherent vasculopathic 
eff ect of homocysteine in the absence of 
available reactive iron. Th e limited benefi t 
so far demonstrated in association with 
decreased homocysteine levels in clinical 
trials8,9 may indicate that such lowered 
levels retain substantial amplifi ed vasculo-
toxic eff ects in the presence of undimin-
ished levels of storage iron.
Figure 1 | Flow-mediated vasodilation 
(FMD, %) before (open bars) and 4 
hours after (solid bars) 100 mg/kg 
oral methionine load with blinded 
coadministration of intravenous placebo 
and dexrazoxane. *P < 0.02 versus placebo. 
(Reproduced from ref. 11.)
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Trials of homocysteine lower-
ing should monitor iron status and 
correlate these data with outcomes. 
However, before such design modifica-
tions are implemented, it would be of great 
interest to assess the eff ects of induced iron 
depletion or defi ciency on homocysteine-
induced endothelial dysfunction. Details of 
the experimental design would diff er from 
those of Zheng et al.11 to allow for the non-
acute period of time required to induce 
iron depletion, for example by phlebotomy. 
As well as its potential importance to our 
understanding of the vasculopathic mecha-
nism of homocysteine, such a study might 
help to confi rm earlier work showing qual-
itative and quantitative similarities in the 
eff ects of iron chelation and iron depletion 
on oxidative stress in other experimental 
systems.16 Iron-dependent amplifi cation of 
the vasculotoxic eff ects of homocysteine, 
together with a possible ferritin-dependent 
increase in homocysteine concentration, 
may be one of several cooperating mecha-
nisms2,13,14,16–18 by which acquisition of 
stored iron increases cardiac risk.
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Fifty years of Balkan endemic 
nephropathy: daunting questions, 
elusive answers
V Batuman1
Balkan endemic nephropathy (BEN) has remained a geographically 
constant endemic for 50 years. Despite extensive research, its etiology 
remains unknown. In the current issue, in a study in one of the earliest 
sites where the endemic was first recognized, Dimitrov et al. confirm the 
persistance of the endemic into a new generation and also identify a 
maternal link in the pathogenesis of BEN. This intriguing finding needs 
to be confirmed in other endemic areas.
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Endemic occurrence of a serious kidney 
disease was fi rst recognized in the 1950s 
in geographically discrete areas along 
the Danube river and its tributaries in 
the Balkans, stretching into Romania, 
Bulgaria, Croatia, Serbia, and Bosnia-
Herzegovina.1–3 Th e disease has existed 
since at least the 1920s, and possibly for 
many decades earlier.3 Although much 
has been written about this tenacious 
endemic over the past 50 years, its pre-
cise etiology is still unknown.
Based on the criteria proposed by 
Danilovic4,5, there is little argument 
regarding the general features of Bal-
kan endemic nephropathy (BEN): a 
slowly progressive chronic tubulointer-
stitial disease that presents insidiously 
with signs of uremia during the fi ft h or 
sixth decade of life, occurring almost 
exclusively in farmers, oft en aff ecting 
multiple family members in a given 
household. Th e male-to-female distri-
bution is equal. Th e disease typically 
effects only those who have lived in 
an endemic area for at least 20 years. 
Individuals who leave an endemic area 
before age 20 are spared, whereas immi-
grants are likely to develop the disease 
15–20 years aft er settling in an endemic 
area, regardless of race or ethnicity.4
Clinically, the disease is character-
ized by tubular proteinuria, usually 
β2-microglobulinuria, profound ane-
mia, and absence of hypertension and 
edema.5 When investigated early dur-
ing its evolution, overt renal disease is 
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